Gbola Amusa
Stock Analyst at Chardan Capital
(1.95)
# 3,007
Out of 4,868 analysts
61
Total ratings
40%
Success rate
2.87%
Average return
Main Sectors:
Stocks Rated by Gbola Amusa
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ADVM Adverum Biotechnologies | Downgrades: Neutral | $200 → $50 | $2.24 | +2,132.14% | 2 | Apr 29, 2021 | |
| TSHA Taysha Gene Therapies | Maintains: Buy | $60 → $68 | $2.46 | +2,643.90% | 3 | Apr 13, 2021 | |
| FBRX Forte Biosciences | Maintains: Buy | $2,875 → $2,625 | $14.66 | +17,805.87% | 4 | Mar 17, 2021 | |
| SLDB Solid Biosciences | Maintains: Buy | $188 → $300 | $4.79 | +6,163.05% | 5 | Mar 16, 2021 | |
| PASG Passage Bio | Maintains: Buy | $36 → $45 | $0.39 | +11,408.95% | 3 | Mar 8, 2021 | |
| MCRB Seres Therapeutics | Upgrades: Buy | $550 → $600 | $7.53 | +7,868.13% | 2 | Mar 5, 2021 | |
| QURE uniQure | Maintains: Buy | $85 → $100 | $14.21 | +603.73% | 4 | Mar 2, 2021 | |
| SYBX Synlogic | Maintains: Buy | $75 → $150 | $1.26 | +11,804.76% | 2 | Jan 13, 2021 | |
| IOVA Iovance Biotherapeutics | Maintains: Buy | $53 → $50 | $1.98 | +2,425.25% | 3 | Oct 6, 2020 | |
| IMVT Immunovant | Maintains: Buy | $35 → $45 | $15.80 | +184.90% | 3 | Aug 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $100 → $115 | $132.46 | -13.18% | 2 | Aug 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $73 → $100 | $44.25 | +125.99% | 1 | Jul 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $84 → $95 | $25.90 | +266.80% | 2 | Jul 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $19 → $15 | $5.64 | +165.96% | 4 | Aug 17, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $90 → $130 | $8.43 | +1,442.11% | 4 | Jul 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $75 → $100 | $1.07 | +9,245.79% | 6 | Mar 27, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $2.5 → $2 | $777.32 | -99.74% | 2 | Jan 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $9.30 | - | 3 | Nov 10, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $300 → $350 | $509.72 | -31.33% | 6 | Dec 12, 2016 |
Adverum Biotechnologies
Apr 29, 2021
Downgrades: Neutral
Price Target: $200 → $50
Current: $2.24
Upside: +2,132.14%
Taysha Gene Therapies
Apr 13, 2021
Maintains: Buy
Price Target: $60 → $68
Current: $2.46
Upside: +2,643.90%
Forte Biosciences
Mar 17, 2021
Maintains: Buy
Price Target: $2,875 → $2,625
Current: $14.66
Upside: +17,805.87%
Solid Biosciences
Mar 16, 2021
Maintains: Buy
Price Target: $188 → $300
Current: $4.79
Upside: +6,163.05%
Passage Bio
Mar 8, 2021
Maintains: Buy
Price Target: $36 → $45
Current: $0.39
Upside: +11,408.95%
Seres Therapeutics
Mar 5, 2021
Upgrades: Buy
Price Target: $550 → $600
Current: $7.53
Upside: +7,868.13%
uniQure
Mar 2, 2021
Maintains: Buy
Price Target: $85 → $100
Current: $14.21
Upside: +603.73%
Synlogic
Jan 13, 2021
Maintains: Buy
Price Target: $75 → $150
Current: $1.26
Upside: +11,804.76%
Iovance Biotherapeutics
Oct 6, 2020
Maintains: Buy
Price Target: $53 → $50
Current: $1.98
Upside: +2,425.25%
Immunovant
Aug 25, 2020
Maintains: Buy
Price Target: $35 → $45
Current: $15.80
Upside: +184.90%
Aug 19, 2020
Maintains: Buy
Price Target: $100 → $115
Current: $132.46
Upside: -13.18%
Jul 28, 2020
Maintains: Buy
Price Target: $73 → $100
Current: $44.25
Upside: +125.99%
Jul 15, 2020
Maintains: Buy
Price Target: $84 → $95
Current: $25.90
Upside: +266.80%
Aug 17, 2018
Downgrades: Neutral
Price Target: $19 → $15
Current: $5.64
Upside: +165.96%
Jul 16, 2018
Maintains: Buy
Price Target: $90 → $130
Current: $8.43
Upside: +1,442.11%
Mar 27, 2018
Maintains: Neutral
Price Target: $75 → $100
Current: $1.07
Upside: +9,245.79%
Jan 10, 2018
Upgrades: Neutral
Price Target: $2.5 → $2
Current: $777.32
Upside: -99.74%
Nov 10, 2017
Upgrades: Buy
Price Target: n/a
Current: $9.30
Upside: -
Dec 12, 2016
Upgrades: Neutral
Price Target: $300 → $350
Current: $509.72
Upside: -31.33%